Amin Harish J, Soraisham Amuchou S, Sauve Reg S
Division of Neonatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
J Paediatr Child Health. 2009 Apr;45(4):219-23. doi: 10.1111/j.1440-1754.2008.01458.x. Epub 2009 Mar 23.
This study aimed to compare the long-term neurodevelopmental outcomes at 36 months adjusted age in preterm infants (birth weight < or = 1250 gm) who received supplementation with L-arginine during the first 28 days of life with controls.
Surviving infants enrolled in a randomised control study of L-arginine supplementation were prospectively followed longitudinally to determine their neurodevelopmental outcomes at 36 months of adjusted age. Neurologic examination and neurodevelopmental assessments were performed by examiners who were unaware of the original treatment assignments.
A total of 132 children (95% of survivors) were evaluated at 36 months adjusted age. In the group given L-arginine, 5 of 61 (8.1%) had major neurodevelopmental disabilities, defined as the presence of one or more of cerebral palsy, cognitive delay (cognitive index <70), bilateral blindness or bilateral hearing loss requiring hearing aids as compared with 9 of 71 (12.6%) in the placebo group (relative risk, 0.64; 95 % confidence interval, 0.22-1.82; P= 0.40).
There is no increase in neurodevelopmental disability in preterm infants who received L-arginine supplementation.
本研究旨在比较出生体重小于或等于1250克的早产儿在出生后前28天接受L-精氨酸补充剂与对照组相比，在矫正年龄36个月时的长期神经发育结局。
纳入L-精氨酸补充剂随机对照研究的存活婴儿进行前瞻性纵向随访，以确定其在矫正年龄36个月时的神经发育结局。神经系统检查和神经发育评估由不知道原始治疗分配情况的检查人员进行。
共有132名儿童（占存活者的95%）在矫正年龄36个月时接受了评估。在给予L-精氨酸的组中，61名中有5名（8.1%）有严重神经发育障碍，定义为存在以下一种或多种情况：脑瘫、认知延迟（认知指数<70）、双侧失明或需要助听器的双侧听力损失，而安慰剂组71名中有9名（12.6%）（相对风险，0.64；95%置信区间，0.22 - 1.82；P = 0.40）。
接受L-精氨酸补充剂的早产儿神经发育障碍没有增加。
